Chairman and CEO, William M. Caldwell, IV and Chief Development Officer, Dr. Pedro Huertas, to Discuss Planned Transition to Clinical Development Company and Other Topics, on Thursday, June 7, at 1:00PM ET
ALAMEDA, CA"June 4, 2007--Advanced Cell Technology, Inc. (OTCBB:ACTC - News) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. Among the topics to be discussed is the Company's entry into a Letter of Intent to purchase Mytogen, Inc. and its Myoblast Program for the treatment of heart failure, and its plans to commence Phase II human clinical trials to treat heart failure using Mytogen's Autologous Myoblast Stem Cell Therapy.
The call will be hosted by William M. Caldwell, IV, Chairman and Chief Executive Officer, and Pedro Huertas, M.D., Ph.D., Chief Development Officer.
William M. Caldwell, IV commented, "This planned acquisition, if completed, will hasten Advanced Cell's transformation from a preclinical development company to a clinical therapeutic company. Our Chief Development Officer, Dr. Pedro Huertas, and I are excited to have the opportunity to discuss this and other company developments with our investors and other interested parties, on Thursday's call.�”
*Details of the call are below. Participants should dial in at least ten minutes prior to the call. Thursday, June 7, 1:00PM ET*
*Live participant dial-in:*
Passcode (for replay only): 517429
Teleconference Replay Available Until: 6/14/07, 11:59 PM
A webcast of the call will be available through Advanced Cell's website, at "www.advancedcell.com":http://www.advancedcell.com/media-gallery-item/advanced-cell-technology-conference-call-and-webcast-to-discuss-recent-developments-and-planned-acquisition-of-mytogen. The webcast will be available for replay through July 7, 2007.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit "www.advancedcell.com":http://www.advancedcell.com
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: James Carbonara or Joseph Kessler, 212-825-3210
Media: Bill Douglass, 212-825-3210